Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/14/2011

NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM.

Chiasma's investigational new drug Octreolin™ is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  The Company successfully completed 4 clinical studies with Octreolin in healthy volunteers, having established a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate.  In addition, Octreolin demonstrated the ability to reduce growth hormone.  No serious adverse safety events were reported in any of the studies.  A trial in patients will commence in October 2011.  Chiasma intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMA equivalent, the Hybrid Application in Europe.

Octreolin is also being developed as a chronic treatment for patients with Portal Hypertension (PHT); a Phase 2 proof of concept trial for this new orphan indication (no drugs are approved for PHT in the US) was initiated in September 2011.  The Company has a pipeline of products that are currently in preclinical development including one in renal disease that will enter the clinic in mid-2012.

About Chiasma

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the portal system and then to the systemic circulation.  The TPE technology not only enables their being converted from injectable to oral, but importantly can result in the development of new indications.

Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary.  It is backed by MPM Capital, ARCH Venture Partners, F-2 Ventures and 7 Med Health Ventures.

Additional information can be found at:  www.ChiasmaPharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chiasmas Octreolin™ (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects
2. Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Heska to Present at LD MICRO Invitational on September 22, 2011
6. Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011
9. PDL BioPharma to Present at Upcoming Investor Conferences
10. Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Robins ... Clinic in Durant, Oklahoma, on Feb. 21. , The celebration began with a ... members, clinic employees, the construction team and tribal leadership. , Choctaw Nation ...
(Date:2/21/2017)... ... ... Doctors on Liens has announced the addition of Mendonca Spine Care Center ... network of doctors in Central and Northern California. Dr. Mendonca specializes in personal injury ... pain, neck pain, hip and knee pain, and headaches. Specializing in non-surgical, spinal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm providing ... is embarking on a six month charity event aimed at raising local support and ... is one of the deadliest diseases in America; more than 7.5 million people die ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... announced the further expansion of its eHealth App xChange™, providing clinical researchers ... of Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... with over 50,000 participants. The connected care demonstration spanned multiple health information ... National Coordinator, roughly 30% of providers have no Health Information Exchange outside of ...
Breaking Medicine News(10 mins):